Clinical Trial Update: Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 dose-finding trial of [177Lu]Lu-NeoB in newly diagnosed and recurrent glioblastoma; study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• [177Lu]Lu-NeoB

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Newly Diagnosed and Recurrent Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING